Interview With Tim Moore, CEO of Havn Life

Two Psychedelic Medicines Companies Run out of Money. What is next for psychedelic stocks? Plus a MindMed Stock Update( MMED / MMED)

Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC

A second domino is falling in the world of psychedelic stock investing.

Last week, Psychedelic Spotlight reported that Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) was halting its psychedelic medicines research, following a “strategic review” undertaken by the company.

In short, they ran out of money.

As I have stated repeatedly, running a psychedelic research company is ridiculously expensive, and many smaller companies with low market caps and little money in the bank will find it hard to survive in a market context of low stock prices.

At the time, I speculated that “we shouldn’t be surprised if this is just the first domino,” and unfortunately, it didn’t take much time for the prophecy to be realized.

On March 19th, psychedelics company Core One Labs (CSE: COOL) (OTC: CLABF) announced that they are “working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies.”

Or, in other words, they too have run out of money and are looking for a financial savior.

This wasn’t particularly surprising. Taking a cursory look at their financials, we can see the dire position the company is in. As of the end of September, the company had $587,000 CAD in the bank, and they were spending more than $5 million per quarter. With a market cap of around $32 million, Core One would have to dilute their stock by more than 15% each quarter to keep spending at the same levels. This, obviously, is an unsustainable proposition.

So, with two psychedelic medicine companies essentially announcing that they no longer have the financial wherewithal to continue operations, does it mean that the end of psychedelic stocks is near?

No, it most certainly does not.

To start, we need to understand that the psychedelics companies that are beginning to falter are the ones who were already in bad financial shape. There are many companies that have strong financials, and do not need to worry about refinancing any time soon. A short and non-exhaustive list of these companies include: atai Life Sciences (Nasdaq: ATAI); MindMed (Nasdaq: MNMD) (NEO: MMED); and Small Pharma (TSXV: DMT) (OTCQB: DMTTF). Even if — and I judge this to be likely — more small-cap psychedelics companies follow Mind Cure and Core One Labs’ lead, the more financially stable companies won’t be affected.

Sources:

PsychedelicSpotlight.com article: https://psychedelicspotlight.com/another-psychedelics-company-core-one-labs-is-crashing-is-industry-in-trouble/

MindCure Press release: https://www.newswire.ca/news-releases/mindcure-provides-update-on-strategic-review-891232484.html

Core One Labs Press Release: https://www.globenewswire.com/news-release/2022/03/19/2406329/0/en/Core-One-Labs-to-Investigate-Soliciting-Investment-and-Potential-Takeover-Opportunities.html

Core One Labs $100/ gram psilocybin: https://www.globenewswire.com/news-release/2022/02/23/2390219/0/en/Vancouver-discovery-will-make-Magic-Mushroom-mental-health-care-cheaper.html

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#PsychedelicStocks #Psychedelics #Investing

The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)

In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.

I had a blast in this interview, and I know you will find it fascinating! Enjoy!

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).

#BrightMinds #PsychedelicStocks #Psilocybin

Compass Pathways is launching a NEW Phase II clinical trial to treat PTSD!!!
The trial will use Comp 360, the company’s synthetic, proprietary version of psilocybin, in conjunction with therapy. This is Compass’ second major trial using Comp 360. They also are using it to treat Treatment Resistant Depression.

On October 3rd, 2021, Compass Pathways (Nasdaq: CMPS) announced the launch of a brand new psychedelic therapy clinical trial, using Psilocybin, the active ingredient in magic mushrooms, to treat PTSD.
The Phase 2 clinical trial will use Comp 360, Compass Pathways’ proprietary, synthetic, cristalline Psilocybin. It will be paired with talk psychotherapy in 20 adults who suffered trauma as an adult, resulting in PTSD.
While using psychedelics for mental health may seem controversial, when it comes to the science, psychedelics like psilocybin and MDMA, when paired with therapy have been shown to work.
For example, recently MAPS completed a Phase III clinical trial using MDMA therapy to treat PTSD, which showed 67% of people improving so much they no longer qualified to be diagnosed as having PTSD (cured?). Another 21% of people improved significantly.

This Compass Pathways trial is exciting, because once it is complete, we will be able to compare the results of their psilocybin trial to MAPS’ MDMA trial, to start to have an understanding of which psychedelic compound works better for treating PTSD.
This news comes as we are waiting for the results of Compass Pathways’ Phase 2b Clinical Trial, testing treating Treatment-Resistant Depression with Comp 360, to be released before the end of the year.
The results of the trial will be significant, as it will be the largest ever clinical trial studying psychedelics, with 216 patients. It will also be the most advanced clinical trial studying psilocybin, being in phase 2b.
In sum, these are very exciting times to be watching Compass Pathways. Controversies surrounding their patents aside, Compass is one of the companies pushing the frontiers of psychedelic medicines, which is very exciting to watch.

Do you think psilocybin assisted therapy could treat PTSD? Let us know in the comments.

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com
Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#CompassPathways #Psychedelics #CMPS

In today’s episode of the Psychedelic Spotlight Podcast, James Hallifax from the Psychedelic Investor YouTube Channel interviews Ian McDonald, CEO of Bright Minds BioScience. For any investors out there, Bright Minds ticker symbol is DRUG on the Canadian CSE and BMBIF on the American OTC market.

In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. Bright Minds is a company working on second and third generation psychedelics to treat a variety of ailments including depression, PTSD, epilepsy, addiction and more. The driving philosophy is that while classic psychedelics such as psilocybin and LSD do show great potential to be used in a therapy setting to treat mental health issues, the compounds also have limitations.

At Bright Minds, the goal is to engineer completely new compounds, often based on the structure of classical psychedelics, that keep the benefits of said drugs while doing away with potential negatives. Important to note is that while psychedelic derived drugs are a focus of the company, they also are creating non-psychedelic compounds for a variety of ailments, including different forms of addiction.

In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
I had a blast in this interview, and I know you will find it fascinating! Enjoy!

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).

#BrightMinds #ThePsychedelicInvestor #PsychedelicStocks